March 2, 2020
IMMUNOPRECISE and EVQLV are collaborating on accelerating the global effort to develop lead vaccine candidates against the SARS-CoV-2 virus.
May 1, 2019
The second day of the show had more company presentations, interviews and a panel discussion on R&D-stage healthcare companies.
September 18, 2017
ImmunoPrecise announced it was awarded the first commercial humanizing antibody project from an undisclosed biotech company.
August 29, 2017
ImmunoPrecise Antibodies announced it is now an approved contract research organization for the development of human monoclonal antibodies with the...
August 3, 2017
ImmunoPrecise Antibodies announced its working towards delivering humanized monoclonal antibodies.
July 24, 2017
Immunoprecise Antibodies announced it increased a previously announced non-brokered private placement financing.
July 4, 2017
ImmunoPrecise Antibodies signed a binding letter of intent with U-Protein Express BV to acquire all issued and outstanding shares of...